bpc-157 human clinical trials evidence safety trial review 2023 2024 Therapeutic Peptides in Aesthetic, Metabolic and The Hidden Risks of BPC‑157:

Adverse effects emerging beyond 12 weeks of continuous use are not documented in published research of any duration in human subjects

The long half-life is driven by albumin binding (greater than 99% bound), reduced DPP-4 degradation due to the Aib8 substitution, and slowed renal clearance of the larger albumin-bound complex

However, some potential risks include: Infection: In rare cases, infections may occur at the injection site

For example, while it is normal for your first few treatments to take place within the same week, usually about one day apart, your subsequent treatments will have a slower frequency

The next step is proper storage

Please note that our reception team supports Kate Stewart and Katie only and is available Tuesday to Saturday